Imatron's electron beam tomography, or EBT, offers clinicians a valuable tool to detect the early presence of heart disease, by looking for calcium deposits that are a surrogate for plaque build-up, and to help them begin treatment or lifestyle changes before heart attacks occur. But adoption or acceptance of EBT has been slow in coming, the result of physician skepticism, consumer ignorance, and most importantly, insurer resistance. Some physicians are skeptical because EBT measures neither restenosis no so-called vulnerable plaque. Things are looking up for Imatron, however. Sales of EBT systems are increasing rapidly due to greater acceptance in the medical community and the launch of the company's own sales force.
by David Cassak
Chances are, particularly if you live in or near a major US metropolitan center, you've heard radio ads, seen news...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
